Ahmet Alacacıoğlu

ORCID: 0000-0003-3428-5932
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Cancer survivorship and care
  • Cancer Treatment and Pharmacology
  • Inflammatory Biomarkers in Disease Prognosis
  • Cancer Diagnosis and Treatment
  • Breast Cancer Treatment Studies
  • Neuroendocrine Tumor Research Advances
  • Gastrointestinal Tumor Research and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • HER2/EGFR in Cancer Research
  • Lung Cancer Research Studies
  • Lung Cancer Treatments and Mutations
  • Brain Metastases and Treatment
  • Metastasis and carcinoma case studies
  • Cancer Risks and Factors
  • Pancreatic and Hepatic Oncology Research
  • Cancer, Lipids, and Metabolism
  • Sarcoma Diagnosis and Treatment
  • Health and Wellbeing Research
  • Genetic factors in colorectal cancer
  • Cancer Genomics and Diagnostics
  • Ovarian cancer diagnosis and treatment
  • Nutrition and Health in Aging
  • Cancer Immunotherapy and Biomarkers

Izmir Kâtip Çelebi University
2016-2025

Ministry of Health of the Russian Federation
2024

Weatherford College
2023

Izmir Atatürk Eğitim ve Araştırma Hastanesi
2014-2019

Center for Rheumatology
2019

Izmir University
2009-2018

Dokuz Eylül University
2004-2016

Izmir Bozyaka Eğitim ve Araştırma Hastanesi
2009-2016

Selçuk University
2016

Ministry of Health
2015

David Miles Joseph Gligorov Fabrice André David Cameron Andreas Schneeweiß and 95 more Carlos H. Barrios Binghe Xu Andrew Wardley Diego Kaen Livia Andrade Semiglazov Vf Mattea Reinisch Shilpen Patel Monika Patre L. Morales Sipahee Lal Patel M. Kaul Teresa Barata Joyce O’Shaughnessy Q. Zhang Binghe Xu Zhimin Shao Xiangyu Wang Cuizhi Geng Xingchen Yan Zhongsheng Tong Kunwei Shen Yongmei Yin Tao Sun James Chih‐Hsin Yang J. Feng Min Yan Yan Wang Qiang Liu S. Zhang Michelino De Laurentiis Armando Santoro Valentina Guarneri Marco Colleoni Clara Natoli Laura Cortesi Sabino De Placido Lorenzo Gianni Francesco Ferraù Lorenzo Livi Alberto Zambelli Lucia Del Mastro Giuseppe Tonini Filippo Montemurro Giulia Bianchi R. Pedersini Salvatore A. Del Prete Giacomo Allegrini Giuseppe Naso Patrizia Vici D. Loirat Audrey Mailliez Franck Priou Olivier Trédan F. Dalenc Christophe Perrin Joseph Gligorov M. Timar David Nadine Dohollou Luís Teixeira Fabien Brocard Antoine Arnaud Suzette Delaloge Jean‐Philippe Spano Luigi Mansi Livia Andrade Fernanda Damian José Luiz Pedrini Sandra M. Aleixo Roberto Hegg Roberto Nery Dantas Mattea Reinisch Marcus Schmidt C. Wenzel E.‐M. Grischke Andreas Schneeweiß Marianne Just Nadia Harbeck Claudia Schumacher Ubong Peters Dorothea Fischer Helmut Forstbauer Rüdiger Liersch Ellen Warner Nathaniel Bouganim C. T. Doyle Julie Price Hiller Ted Vandenberg Michel Pavic Andrew Robinson Gloria Roldan Urgoiti Nadia Califaretti Ahmet Alacacıoğlu Mahmut Gümüş Bülent Yalçın

In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...

10.1016/j.annonc.2021.05.801 article EN cc-by-nc-nd Annals of Oncology 2021-07-01
Jonathan W. Goldman Mikhail Dvorkin Yuanbin Chen Niels Reinmuth Katsuyuki Hotta and 95 more Dmytro Trukhin Galina Statsenko Maximilian J. Hochmair Mustafa Özgüroğlu Jun Ho Ji Marina Chiara Garassino Олександр Войтко Artem Poltoratskiy Santiago Ponce Francesco Verderame Libor Havel Igor Bondarenko Andrzej Każarnowicz György Losonczy Nikolay Conev J. Armstrong Natalie Byrne Piruntha Thiyagarajah Haiyi Jiang Luís Paz-Ares Mikhail Dvorkin Dmytro Trukhin Galina Statsenko Олександр Войтко Artem Poltoratskiy Igor Bondarenko Yuanbin Chen Andrzej Każarnowicz Luís Paz-Ares Mustafa Özgüroğlu Nikolay Conev Maximilian J. Hochmair Otto C. Burghuber Libor Havel İrfan Çiçin György Losonczy В. Моисеенко Mustafa Erman Dariusz M. Kowalski Marek Z. Wojtukiewicz Hryhoriy Adamchuk Alexander Vasilyev Serhii Shevnia Spartak Valev Niels Reinmuth Jun Ho Ji Amelia Insa Grygorii Ursol Anne C. Chiang Sylvia Hartl Zsolt Horváth Gábor Pajkos Francesco Verderame Katsuyuki Hotta Sang‐We Kim Alexey Smolin Tuncay Göksel Shaker R. Dakhil Jaromı́r Roubec Krisztina Bogos Marina Chiara Garassino Robin Cornelissen Jong-Seok Lee M.R. García Campelo Marta López Brea Ahmet Alacacıoğlu Ignacio Casarini Rumyana Ilieva Ivan Tonev A Somfay Jair Bar Alona Zer Mauro Minelli Roberta Bartolucci Fausto Roila Haruhiro Saito Koichi Azuma Gyeong‐Won Lee Alexander Luft M. Urda Juan Ignacio Delgado Mingorance M. Majem Tarruella David R. Spigel Krassimir Koynov Milada Zemanová Jens Panse Christian Schulz Zsolt Pápai Székely Veronika Sárosi Angelo Delmonte Anna Bettini Makoto Nishio Isamu Okamoto Lizza E.L. Hendriks Sławomir Mańdziuk

10.1016/s1470-2045(20)30539-8 article EN The Lancet Oncology 2020-12-05
Miguel Martín Elgene Lim Mariana Chávez‐MacGregor Aditya Bardia Jiong Wu and 95 more Qingyuan Zhang Zbigniew Nowecki Felipe José Silva Melo Cruz R. N. Safin Sung‐Bae Kim Christian Schem Alberto J. Montero Sarah Khan Reeti Bandyopadhyay Heather M. Moore Mahesh Shivhare Monika Patre Jorge Martinalbo Laura Roncoroni Pablo Perez-Moreno Joohyuk Sohn G. Aguil Marcos E. Alfie Valeria Cáceres Guillermo Lerzo Sandra A. Ostoich F. Boyle Elgene Lim Hayes Martin Catherine Oakman Felipe Melo Cruz Fábio Franke André Mattar E.H. Silva Katsuki Arima Tiscoski Wei Chen Wěi Li Zhongsheng Tong Jing Wang Shaomeng Wang X. Wang Jiong Wu Xiao‐Yuan Wu Ju Yang Q. Zhang Till‐Oliver Emde G. Gaffunder Carsten Hielscher Michael P. Lux Christian Schem Manfred Welslau Claudia Schumacher I. Kuchuk T Peretz Larisa Ryvo R. Yerushalmi Hee Dong Chae Y.S. Chae Seock‐Ah Im Hwa Jung Kim Jie‐Hyun Kim S.-B. Kim Jung Eun Lee Y. H. Park Joohyuk Sohn Michał Jarząb Monika Nowaczyk Zbigniew Nowecki Tadeusz Pieńkowski Marek Z. Wojtukiewicz Piotr J. Wysocki E. Fomin I. P. Ganshina Nikolay Kislov М. В. Копп Н. В. Коваленко Y. Makarova Marina Matrosova Р. В. Орлова Artem Poltoratsky Р. Р. Сафин Р. А. Зуков A. Wong Yoon Sim Yap M.A. Coccia-Portugal Nicolaas H. Fourie R. Khanyile L. Schoeman Ta‐Chung Chao S.-T. Chen Wei‐Pang Chung Yin‐Hsun Feng Yung‐Chang Lin Thitiya Dejthevaporn Napa Parinyanitikul Chirawadee Sathitruangsak Areewan Somwangprasert Piyawan Tienchaianada Ahmet Alacacıoğlu Efnan Algın

PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...

10.1200/jco.23.01500 article EN cc-by-nc-nd Journal of Clinical Oncology 2024-03-27

Abstract Purpose : Burnout is associated with decreased job performance and commitment, predicts stress‐related health problems, low career satisfaction. The specific objectives in our study were to assess the levels of burnout investigate interrelationships between demographic characteristics health‐care professionals working cancer patients Turkey. Methods A questionnaire‐based was conducted 77 physicians 56 nurses an oncology clinic at university hospital. We used quantitative survey...

10.1002/pon.1432 article EN Psycho-Oncology 2008-10-22

PURPOSE Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction (GC). We assessed FGFR2b prevalence nearly 3,800 tumor samples as part of the prescreening process for a global phase III study patients with newly diagnosed advanced or metastatic GC. METHODS As June 28, 2024, 3,782 from prescreened 37 countries FORTITUDE-101 trial (ClinicalTrials.gov identifier: NCT05052801) were centrally tested...

10.1200/po-24-00710 article EN JCO Precision Oncology 2025-01-01

Objective The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score the Geriatric Nutrition Risk Index (GNRI) are used as prognostic factors in different types of cancers. In this study we analyzed value HALP GNRI calculated prior to first-line treatment patients diagnosed with de novo metastatic non-small cell lung cancer (mNSCLC). Materials methods De mNSCLC were retrospectively evaluated from January 2016 December 2019. Patients Driver’s mutation, severe comorbidities, active...

10.3389/fnut.2022.905292 article EN cc-by Frontiers in Nutrition 2022-08-18

<b><i>Background:</i></b> Several studies evaluating the prognostic factors of gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs) have been published. The neutrophil-lymphocyte ratio (NLR) platelet-lymphocyte (PLR) accepted as for cancer patients. <b><i>Materials Methods:</i></b> This study included 132 patients diagnosed with GEP-NETs. Peripheral blood samples were collected before pretreatment period....

10.1159/000445045 article EN Chemotherapy 2016-01-01

The aim of the current study are to determine depression levels adult oncology patients in cancer treatment phase and identify both cancer-related stigma factors affecting their levels.In this correlational study, 303 who had been treated at a medical outpatient clinic were surveyed using convenience sampling method. "questionnaire for measuring attitudes toward - patient version," sociodemographic characteristics questionnaire, beck inventory used. A multivariable linear regression model...

10.4103/apjon.apjon_45_19 article EN cc-by-nc-nd Asia-Pacific Journal of Oncology Nursing 2019-12-10

We aimed to investigate anxiety, depression and sexual satisfaction levels the effects of anxiety upon Turkish breast cancer patients their partners.Data were collected from one hundred partners, using three forms: covering information about socio-demographic characteristics patients, Hospital Anxiety Depression Scale (HADs) Golombok-Rust Inventory Sexual Satisfaction (GRISS).The frequencies, avoidance touch subscores statistically significantly high in patients. Among those with scores,...

10.7314/apjcp.2014.15.24.10631 article EN cc-by Asian Pacific Journal of Cancer Prevention 2015-01-22

To investigate the variables of quality life (QoL) among Turkish patients with colorectal cancer (CRC).In this prospective study we investigated QoL CRC patients. Two hundred and twenty two were included. The sociodemographic form European Organization for Research Treatment Cancer Quality Life Questionnaire (EORTC QLQ-C30) used.The group consisted 142 males (64%) 80 females (36%). mean patient age was 55.68±11.387 years. majority (36.9%) had local disease while advanced-stage locally...

10.1093/jjco/hyv051 article EN Japanese Journal of Clinical Oncology 2015-04-10

Hepatocellular cancer (HCC) is one of the important health problems in Turkey. We aimed to determine clinical and demographic features HCC Turkish population evaluate prognostic survival features.Two hundred twenty-one patients with from five hospitals Turkey are included this study.In 44.4% 221 hepatitis B virus 21.3% C were found be responsible for etiology. It has been shown that developed on cirrhosis basis 74.2% patients. was presented single solitary nodule 69.2% Non-liver metastasis...

10.1093/jjco/hyn082 article EN Japanese Journal of Clinical Oncology 2008-08-28

Objective Endothelial dysfunction is present in ankylosing spondylitis (AS). However, the etiology of events still unclear. The aim study was to investigate whether there are abnormalities nitric oxide (NO) metabolism and endothelin-1 (ET-1) AS patients. Methods Subjects without any classical cardiovascular (CV) risk factors were studied. Fasting glucose, serum lipids, high sensitive CRP (hsCRP), ESR, asymmetric dimethylarginine (ADMA) ET-1 Patients also evaluated with Bath Ankylosing...

10.2169/internalmedicine.48.2193 article EN other-oa Internal Medicine 2009-01-01

Background: It is well known that tumor-infiltrating lymphocytes (TIL) and, to a lesser extent, peripheral hematologic parameters from patients with cancer have effect on prognosis. The aim of this study was evaluate the p

10.3233/cbm-130331 article EN Cancer Biomarkers 2013-05-20

249 Background: Urotensin-II is a small somatostatin-like cyclic peptide characterized by its potent vasoconstrictor activity. (UT-II) and receptor (UTR) have been shown to play role in the formation of different epithelial cancers. To date, many studies reported prostate cancer that provide genetic contributions with diagnostic, prognostic therapeutic potential for carcinogenesis. However, urotensin-II carcinogenesis has not yet elucidated. There are several limitations using PSA as...

10.1200/jco.2025.43.5_suppl.249 article EN Journal of Clinical Oncology 2025-02-10

Amaç: Meme kanseri, kadınlar arasında en yaygın kanser türü olup, özellikle gelişmekte olan ülkelerde insidans ve mortalitesi artmaktadır. Tarama programları, hastalık belirtileri ortaya çıkmadan önce hastalığı tespit etmeyi amaçlar. Türkiye'de 40-69 yaş arası için iki yılda bir mamografi taraması önerilmektedir. Bu çalışmanın amacı, meme kanseri tanısı almış tedavileri tamamlanmış hastaların, tanı öncesinde aile hekimlerinden hizmeti alma durumlarını değerlendirmektir. Gereç Yöntemler:...

10.24938/kutfd.1520182 article TR Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 2025-04-26

The cardiac toxicity of LV5FU2 (de Gramont) regimen which is a widely used chemotherapy in gastrointestinal system cancers not well defined. We aimed to evaluate the impact this on rhythm. Two Holter ECG recordings were obtained all patients with treated as first-line (one before and second during first 24 h chemotherapy). Records reviewed for heart rate, rhythm, atrial premature complexes (APC), ventricular (VPC), grades according Lown-Wolf grading ST segment changes. evaluated 27 patients....

10.1111/j.1742-1241.2007.01323.x article EN International Journal of Clinical Practice 2007-04-10

Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints. Mediators such as macrophage migration inhibitory factor (MIF) interleukin-10 (IL-10) are thought to be involved in several conditions, including AS. Proinflammatory cytokines regulate production of oxidative stress markers, nitric oxide (NO) malondialdehyde (MDA). Although lipid peroxidation have been reported AS, association AS with commonly known markers remains uncertain. We...

10.1007/s10165-009-0230-9 article EN Modern Rheumatology 2009-09-28
Coming Soon ...